Complete Response of Liver Cancer to Sorafenib in a Patient with Hemochromatosis
Author Information
Author(s): Brian J So, Tanios Bekaii-Saab, Mark A Bloomston, Tushar Patel
Primary Institution: The Ohio State University Medical Center
Hypothesis
Can sorafenib lead to complete remission in patients with metastatic hepatocellular carcinoma?
Conclusion
This case demonstrates a complete clinical response to sorafenib in a patient with metastatic hepatocellular carcinoma.
Supporting Evidence
- The patient had a significant reduction in tumor size and alpha-fetoprotein levels after one month of sorafenib therapy.
- No evidence of disease recurrence was noted six months after stopping sorafenib treatment.
- This case represents the first known complete response to sorafenib in metastatic hepatocellular carcinoma.
Takeaway
A 78-year-old man with liver cancer got better after taking a medicine called sorafenib for six months, and he hasn't had any signs of cancer since.
Methodology
The patient was treated with sorafenib at 400 mg, twice daily, for six months, with follow-up imaging and alpha-fetoprotein monitoring.
Potential Biases
The case report is based on a single patient, which may introduce bias in the interpretation of the results.
Limitations
The response observed is unique and may not be generalizable to all patients with metastatic HCC.
Participant Demographics
A 78-year-old male with a history of hereditary hemochromatosis and multiple comorbidities.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website